Curriculum · Screening (National/International)
Prostate cancer screening
What it is
Prostate cancer screening rests on the PSA, and what makes it a hard decision is that its harms are as well described as its benefit. Prostate cancer sits high among the causes of cancer death in men: for 2011 to 2015 the leading causes of cancer death in men were lung cancer at 53.8 deaths per 100,000 per year, prostate cancer at 19.5, colorectal cancer at 17.3 and pancreatic cancer at 12.6.
BPH does not change the screening. In patients with BPH the risk of developing prostate cancer is not higher than that of the general male population, so the standard PSA screening protocol can be followed, and TURP does not reduce the risk of developing prostate cancer.
Causes and risk
The risk factors named are family history and black race. The age band offered is 55-69, and there it is a shared decision-making approach, because of false positives predisposing the patient to invasive procedures and a high detection rate of clinically insignificant cancers leading to overdiagnosis. The method is PSA.
How it is diagnosed
Two signs carry it: an elevated PSA and an abnormal DRE. PSA elevation is often present in men with prostate cancer, and the likelihood of prostate cancer increases with a more elevated PSA value. But PSA is not specific for malignancy, and an elevated PSA can occur in a number of benign conditions, and a PSA result in the normal range does not rule out the possibility of prostate cancer. The rectal examination has a limit of its own: DRE may detect prostate nodules, induration or asymmetry that can occur with prostate cancer, but prostate cancer is often not detectable by DRE, because DRE can only detect tumors in the posterior and lateral aspects of the prostate that are palpable via the rectum. Read as a Tumor Marker, its clinical use is screening for prostate cancer, which is controversial because of overdiagnosis, and monitoring progression or recurrence; and it is elevated in benign conditions like BPH and prostatitis. Where the rectal examination finds a hard, discrete nodule on the prostate gland, transrectal ultrasound-guided prostate biopsy is the best test to establish the diagnosis, and that stands even when a PSA taken 3 months earlier was normal. Ultrasound of the prostate without biopsy fails to give a diagnosis; percutaneous prostate biopsy is image-guided and is usually reserved for men with anal canal stenosis or a previous abdominal-perineal resection; transurethral resection of the prostate is indicated in benign prostatic hypertrophy and not for a posterior prostate mass; and urine cytology is not indicated in the work-up of a prostate mass.